CAR-T Cell Therapy Avaliable at GoBroad Healthcare Group (GHG)

GoBroad has accumulated extensive clinical research and practical experience in the field of cellular immunotherapy. Through long-term, large-scale clinical practice in CAR-T therapy, GoBroad has developed systematic capabilities in CAR-T treatment and comprehensive patient management, and continues to provide CAR-T therapy to eligible patients. To date, GoBroad has delivered more than 6,000 CAR-T treatments, supported by a comprehensive management system covering pre-treatment evaluation, risk management during treatment, adverse event management, and post-treatment follow-up.

Meanwhile, GoBroad’s expert teams continue to contribute high-quality research in CAR-T therapy. More than 60 CAR-T-related papers have been published in leading international medical journals, including Nature Medicine, The Lancet Oncology, Journal of Clinical Oncology, Journal of Hematology & Oncology, and Blood. In addition, more than 160 CAR-T-related studies have been selected for presentation at major international conferences, including ASH, ASCO, EHA, and EBMT, with over 40 oral presentations. These sustained clinical and scientific contributions demonstrate GoBroad’s strengths in clinical practice, research innovation, and integrated treatment, supporting the delivery of professional and comprehensive CAR-T care to more patients.